Compare · ESTA vs STE
ESTA vs STE
Side-by-side comparison of Establishment Labs Holdings Inc. (ESTA) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESTA and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $23.05B, about 10.7x ESTA ($2.15B).
- STE has been more active in the news (16 items in the past 4 weeks vs 5 for ESTA).
- STE has more recent analyst coverage (17 ratings vs 14 for ESTA).
- Company
- Establishment Labs Holdings Inc.
- STERIS plc (Ireland)
- Price
- $72.15+0.11%
- $236.43-0.47%
- Market cap
- $2.15B
- $23.05B
- 1M return
- -
- +8.14%
- 1Y return
- -
- -4.93%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 5
- 16
- Recent ratings
- 14
- 17
Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest ESTA
- Establishment Labs upgraded by Citigroup with a new price target
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- SEC Form 10-Q filed by Establishment Labs Holdings Inc.
- Establishment Labs Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Establishment Labs® Reports Second Quarter 2026 Financial Results
- SEC Form SCHEDULE 13G filed by Establishment Labs Holdings Inc.
- Establishment Labs® to Announce Second Quarter 2026 Financial Results on August 6
- Director Chacon Quiros Juan Jose was granted 11,315 shares, increasing direct ownership by 25% to 56,508 units (SEC Form 4)
- SEC Form 4 filed by Director Lewin Nicholas Sheridan
- Amendment: Director Harris Taylor C. was granted 3,722 shares (SEC Form 4)
Latest STE
- SEC Form 144 filed by STERIS plc (Ireland)
- SEC Form 4 filed by Director Shapiro Louis
- Director Sohi Mohsen exercised 4,058 units of Ordinary Shares at a strike of $86.23 and sold $956,795 worth of Ordinary Shares (4,058 units at $235.78) (SEC Form 4)
- SEC Form 4 filed by Director Shah Nirav R
- SEC Form 4 filed by Director Martin Paul Edward
- SEC Form 4 filed by Director Boulud Pierre
- SEC Form 4 filed by Director Feldmann Cynthia L
- SEC Form 4 filed by Director Holland Christopher S
- SEC Form 4 filed by Director Alegria Esther M.
- SEC Form 144 filed by STERIS plc (Ireland)